Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Monotherapy for Renal Protection in Liver Transplant
NCT04063865Phase 3Terminated
- Sponsor
- Indiana University
- Start
- May 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in Liver transplant rejection (2 arms), sponsored by Indiana University. Primary endpoint: Glomerular Filtration Rate at 36 months. Started May 2019; status: terminated.
02
Drugs
everolimus
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT04063865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04063865.